键凯科技 (688356.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

39.7x

Market Cap

CNY 7.52B

MomentumView details →

1D Return

+15.52%

YTD Return

—

RSI (14)

43.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

39.7x

Market Cap

CNY 7.52B

RSI (14)

43.3

MomentumView details →

1D Return

+15.52%

YTD Return

—

ProfitabilityView details →

Gross Margin

66.45%

Net Margin

22.01%

EBITDA Margin

34.58%

ROE (TTM)

5.39%

ROA (TTM)

5.09%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+41.85%

EPS YoY

+162.27%

FCF YoY

+6.00%

Revenue CAGR 3Y

−7.89%

EPS CAGR 3Y

−31.04%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.37

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

10.41x

Quick Ratio

9.21x

Div Yield

0.39%

Div Rate

CNY 0.31

Div Growth 1Y

+106.67%

Financials snapshotView financials →

Revenue (TTM)

328.26M

Net Income (TTM)

72.23M

Op. CF (TTM)

135.08M

Next earningsNov 4, 2026 →

Latest newsMore news →

Jiankai Technology announced the termination of its wholly-owned subsidiary Tianjin Jiankai's phase III clinical study of polyethylene glycol irinotecan (JK1201I) for relapsed or progressive extensive-stage small cell lung cancer, and will fully impair the capitalized R&D amount of 70.6411 million yuan, reducing its 2026 half-year total profit by the same amount.11d ago

Wu Kaiting, a shareholder holding more than 5% of Jiankai Technology, completed a reduction of 3% of the company's shares through centralized bidding and block trades between July 15 and August 24, 2026.12d ago

Similar companies

技源集团603262.SH 奥锐特605116.SH 老百姓603883.SH Definium Therapeutics, Inc.DFTX Beijing Tong Ren Tang Chinese Medicine Company Limited03613.HK 亚宝药业600351.SH Find similar companies →

Latest newsMore news →

Jiankai Technology announced the termination of its wholly-owned subsidiary Tianjin Jiankai's phase III clinical study of polyethylene glycol irinotecan (JK1201I) for relapsed or progressive extensive-stage small cell lung cancer, and will fully impair the capitalized R&D amount of 70.6411 million yuan, reducing its 2026 half-year total profit by the same amount.11d ago Wu Kaiting, a shareholder holding more than 5% of Jiankai Technology, completed a reduction of 3% of the company's shares through centralized bidding and block trades between July 15 and August 24, 2026.12d ago